← All stories
Startup story

Nuxa Diagnostics wants disease tests done in the field in 30 minutes

Nuxa Diagnostics, a Wageningen University spin-off, is building a handheld test that detects pathogens in crops, water and animals on site in about 30 minutes.

Nuxa Diagnostics co-founders Daniel Besselink and Patrick Barendse in white lab coats in a Wageningen University lab
Photo: Nuxa Diagnostics

Nuxa Diagnostics, a young spin-off of Wageningen University in the Netherlands, is building a handheld test that finds a disease where the sample is taken, in about 30 minutes, instead of after days of waiting for a central lab. It is aimed first at growers and the people who test water, crops and animals, and it was founded in October 2026 by Daniel Besselink and Patrick Barendse.

What does Nuxa Diagnostics do?

Today, finding out what is making a plant, an animal or a person sick usually means taking a sample, sending it to a central laboratory and waiting days for the result. Only then can anyone act. Nuxa wants to close that gap with a lab-grade test that fits in the palm of your hand.

The test is based on an enzyme called prokaryotic Argonaute, which can be guided by a short RNA sequence to find a specific piece of DNA or RNA. Because that guide can be changed, the same test can be pointed at a new pathogen without redesigning everything. In its press release of 28 October 2026, the company says it can detect viruses, bacteria and fungi with high specificity, including specific mutations. Unlike PCR, the lab standard, it works at one constant temperature, which is what makes it usable outside a lab.

According to IO+, the plan is to sell a small handheld analyser as a one-off purchase, with a cartridge per test. Prices have not been set yet.

Who is it for?

Nuxa's website names four areas: agriculture and horticulture (plant disease and irrigation water), water and buildings (drinking water and Legionella in HVAC systems), veterinary health (finding sick animals and tracking spread within a herd) and human health, from Ebola to antibiotic-resistant infections. Agriculture is the first example the founders give. Daniel Besselink told IO+ that the company cannot cover thousands of pathogens at once, so choosing the first application carefully matters.

For foundersGet your startup featured for freeBuilding something new in Europe? We write a free article about it. Sharing it on LinkedIn is welcome, never required.Pitch your startup →

Who is behind Nuxa Diagnostics?

Patrick Barendse (CTO) earned his PhD cum laude at Wageningen University on Argonaute proteins, in the lab of Daan Swarts, where the technology was developed. Daniel Besselink (CEO) was previously Chief of Staff at the climate tech scale-up NeoCarbon. The technology comes from the Laboratory of Biochemistry at Wageningen University and is protected by a granted European patent and a US patent application.

"I really believe we can solve a great many problems with faster diagnostics, because so many diseases are discovered too late," says Daniel Besselink, co-founder and CEO (translated from Dutch). Patrick Barendse, co-founder and CTO, adds: "What makes this technology special is that it is programmable: we can aim it at a new pathogen by changing only a short guide sequence, without redesigning the whole test."

What is new?

Nuxa was founded in October 2026 and announced itself on 28 October. It is funded through the Biotech Booster programme and wants to scale the technology from pilot to full industrial scale over the coming years. IO+ reported on 10 November 2026 that pilots are planned from the start of 2027. The company is now looking for customers, partners and investors, and invites growers, water utilities and research partners to get in touch.

Quick facts

  • Company: Nuxa Diagnostics
  • What it does: a handheld molecular test that detects pathogens on site in about 30 minutes
  • For whom: growers, water and building managers, veterinarians and, later, human health
  • Based in: Wageningen, the Netherlands
  • Founded: October 2026, by Daniel Besselink (CEO) and Patrick Barendse (CTO), as a Wageningen University spin-off
  • Funding: Biotech Booster programme
  • Pricing: not yet set (analyser plus a cartridge per test)
  • Website: nuxa.bio

Sources: information and press release from Nuxa Diagnostics, nuxa.bio, IO+ (10 November 2026) and HortiDaily (28 October 2026). More young companies: New startups in the Netherlands (2026).

Learn more at nuxa.bio.

Building something new?Get your startup or brand featured for free. No fees and no conditions.
Pitch your story →

Featured in this story? Get your share kit: a ready LinkedIn post and a badge for your website.